With the Second-Generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the “Retrievable Era” using TAVR products
The TaurusElite® Transcatheter Aortic Valve Replacement System (hereinafter referred to as “TaurusElite®“) developed by Peijia Medical (9996.HK) is approved for marketing by the National Medical Products Administration (NMPA) in June 2021 (Reg. No. GXZZ 20213130464). This approval will accelerate the transition of China TAVR practice into retrievable era. TaurusElite® is the second-generation TAVR system developed by Peijia…
